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ABSTRACT 
 
To date, breast cancer (BC) research is mainly studied with cell lines. These cells were passaged multiple times, 
acquiring phenotypes, additional mutations and epigenetic changes. These changes make the passaged cell lines 
different from the original malignancy. Thus cell lines, although useful as models could be improved with additional 
studies with primary BC. It is difficult to obtain malignant cells from breast tissues without contamination from 
surrounding healthy cells. Selection and expansion of malignant cells from surgical tissues have proved to be daunting 
tasks. This study describes a reliable and reproducible method for isolating and expanding malignant cells from 
surgical breast tissues. The method uses co-cultures with BM stroma to select for the cancer cells while the healthy cells 
undergo rapid cell death. Studies are described to show the cloning efficiencies and sensitivity of the method using 
surgical samples of varying sizes, different stages of BC, and samples from needle biopsies. 
 
 
INTRODUCTION 
 
Breast cancer (BC) metastasis to the bone marrow (BM) 
correlates with poor prognosis (1). Seemingly curative 
therapies in patients with both metastatic and non-
metastatic BC have recurrence of BC cells from the BM 
(1). Such resurgence could occur even twenty years after 
remission (1, 2). Based on these reports, it is 
hypothesized that BC cells (BCCs) entering and 
surviving in BM are either subsets of BCCs with unique 
properties, or they are located in an area to protect them 
from current treatment modalities. The ability of BCCs 
resurging from the BM is consistent with preference for 
this organ (2). Since similar resurgence occurred even in 
cases with early stages of BC it appears BCCs might have  
 
 
entered BM long before the tumor could be detected by 
current clinical methods. 
 
BM toxicity limits the dose of current cancer therapies 
(3). Thus, if a special type of BCC is within specialized 
region of the BM, then targeting BCCs in BM would be a 
clinical challenge. To mimic in vivo behavior of BCCs, it 
is essential to use primary BCCs in experiments since 
these cells would have limited divergence as might occur 
with cell lines. 
 
Studies using BC cell lines with varying degrees of 
metastatic potentials are models in the majority of 
laboratories. Use of cell lines is convenient due to their 
availability through tissue depository banks, and     
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simplicity with regards to culture maintenance. Some cell 
l i n e s  h a v e  b e e n  d i s t r i b u t e d  w i t h i n  l a b o r a t o r i e s  s o  t h a t  
relevant information regarding their source and number 
of passages are lost. This could lead to heterogeneity 
within a particular line and lead to seemingly 
irreproducible data among laboratories. In summary, BC 
cell lines might not show consistent results, and might 
not accurately represent the behavior of cancer cells in 
vivo. 
 
Another disadvantage for BCCs subjected to multiple 
passages relates to their genomic instability resulting in a 
population of cells with varying degrees of tumorigenic 
potential. It is advisable to verify studies from cell lines 
with primary BCCs. Another limitation when primary 
BCC are used pertains to the size of surgical tissues. For 
small samples, clinical analyses have first preference 
leaving no sample for experimental analyses. These 
limits are evident when samples are obtained by non-
invasive methods such as needle biopsies. Another major 
disadvantage is difficulty in separating malignant and 
normal cells in surgical tissues. 
 
Studies from our laboratory reported a novel method to 
isolate primary BCCs in co-cultures with BM stroma. The 
method has been proven effective and sensitive even for 
needle biopsies. The co-culture method is also applied in 
studies to understand the behavior of BCCs within BM. 
Methods to use primary BCCs is underscored by recent 
findings on SDF-α-CXCR4 interactions in BC metastasis 
(4). Malignant breast tissue, unlike healthy tissue show 
high expression of CXCR-4. Since stromal cells produce 
SDF-1α (8), BCCs expressing CXCR4 could be attracted 
and retained to organs that express SDF-1, such as BM, 
lung, and liver (4). The density of CXCR-4 on BCC is 
proportional to the invasiveness of the cancer (5). Recent 
studies with mice show that there might be two subtypes 
of BCC that enter the BM (6). The aforementioned 
examples on SDF-1-CXCR4 argue for studies with 
primary BCCs to understand the fine-tuned mechanisms 
facilitating BC metastasis to the BM, and late stage 
resurgence in BM. 
 
Previous studies show BCCs with high proliferative 
potential is found within the central/cellular areas of the 
B M  c a v i t y  ( 6 ) .  A n o t h e r  B C  s u b s e t  w i t h  l o n g  d o u b l i n g  
times is located close to the endosteum (6). Defining the 
properties of BCC subtypes in the BM and 
understanding the mechanisms involved in BCC entry in 
the BM are keys to improve cancer treatment and 
eradication. The method to isolate malignant cells will 
provide the opportunity to compare BCCs at different 
stages of the cancer, and also those that enter the BM at 
different periods during the course of the disease. To 
identify the cells entering early in different organ could 
lead to understandings on the mechanisms of entry and 
the signature of these cells, leading to cancer prevention, 
partly by early detection. 
 
MATERIALS AND METHODS 
 
Reagents and antibodies 
 
α-Minimum Essential Medium (α-MEM), glutamine and 
hydrocortisone were purchased from Sigma (St. Louis, 
MO). Fetal Calf sera (FCS) and Horse Sera (HS) were 
purchased from Hyclone Laboratories (Logan, UT). PE- 
cytokeratin mAb, PE- rat anti mouse kappa and PE- 
CD14 mAb were purchased from BD Bioscience (San 
Jose, CA). Prolyl-4-hydroxylase mAb was purchased 
from Dako (Glostrup, Denmark). Anti-Epithelial and 
anti-fibroblast were purchased from Miltenyi Biotec, 
Auburn, CA) respectively.  
 
Cell lines 
 
The following cell lines were purchased from American 
Type Culture Collection (Manassas, VA): Tumorigenic 
cell lines, T47D and MDA-MB-330 and non-tumorigenic 
cell lines, MCF12A and MCF 10A. 
 
Primary breast tissue   
 
Excess tissues were taken from samples of surgical 
procedures. The surgical interventions w e r e  d o n e  i n  
patients diagnosed with different stages of BC. At the 
time of surgery patients were not on any medication. 
Samples were provided from two sources. The major 
source of breast tissue was from Brookdale Hospital 
(Brooklyn, NY). Use of breast tissues followed a protocol 
approved by the institutional review board of University 
of Medicine and Dentistry of New Jersey (Newark, NJ) 
and Brookdale Hospital (Brooklyn, NY). Patient samples 
were also provided by the Cooperative Human Tissue 
Network. Table 1 shows representative subsets of 
patients’ profile of tissues. Excess samples from needle 
biopsies were also obtained from Brookdale Hospital.     
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Table 1: Single cell suspensions were prepared from surgical tissues 
of different stages of BC. 
  Stage of BC 
  M  0 
n = 4 
M  I 
n = 5 
M  III 
n = 10 
Starting population  1012 ± 50  5180 ± 32  4135 ± 22 
Total cells at P4  2 x 106 ± 55  6 x 106 ± 90  5 x 106 ± 66 
Fold expansion  2.0 x 103  1.2 x 103  1.2 x 103 
Colonies/103  820 ± 23 744  ± 14 868  ± 15 
Cloning efficiencies  82% 74% 87% 
Fibroblasts were depleted from surgical breast tissues. Cells retrieved 
(starting population) were placed in co-cultures with BM stroma. At 
confluence, cytokeratin positive cells were selected and then placed in 
multiple passages of co-cultures with fresh BM stroma. The mean ± SD 
of total cytokeratin positive cells are shown for passage 4 (P4). At P4 
cells were studied in clonogenic assays. 
 
Cell suspension from surgical breast tissues 
 
Cells (normal and malignant) were retrieved from the 
breast tissues using the following two methods: a) 
flushing with a 1-cc syringe containing any type of cell 
culture media; and b) dislodging cells with serrated-end 
forceps. Fibroblasts were removed using double positive 
selection with anti-fibroblast microbeads. Depletion of 
fibroblasts was verified by flow cytometry with FITC-
anti-fibroblasts and PE-anti-cytokeratin. Viability of 
selected cells was >95%, by trypan blue exclusion. 
Biopsies from three different patients with stage 0 BC 
(Table 1) were obtained and also cleared of fibroblasts (as 
above). Fibroblast-depleted cells from patients with BC 
are hereafter referred as breast cells because the cells 
might contain both malignant and normal cells. After co-
culture and selection of anchorage independent growth, 
the cells were referred as primary BCCs (6). The cells 
were passaged at least four times before use in assays. 
Cryopreservation up to two years did not alter their 
anchorage-independent properties, nor their ability to 
form co-cultures. 
 
Preparation of BM stroma   
 
BM aspirate, 107 nucleated cells from healthy donors 
between ages 18-25 years were added to 25 cm2 tissue 
culture flasks (Falcon 3109). After selection, stromal cells 
were resuspended in stromal culture medium II, 
consisting α-MEM with 20% FCS. Plates were incubated 
3 days at 37°C; mononuclear cells were separated by 
Ficoll-Hypaque density gradient and then replated in 
fresh medium. Cells were incubated until confluency, 
approximately 3 weeks. During this time, cultures were 
fed weekly by replacing fifty percent of the culture 
medium with fresh medium. At confluence trypsin-
sensitive, adherent cells were passed at least five times. 
Flow cytometry studies indicate stromal cells were CD14 
(-) and prolyl 4-hydroxylase (+). 
 
Co-cultures with established cell lines  
 
BCCs refer to both cell lines and primary cells. 
Equivalent numbers of BCCs and BM stromal were co-
cultured in stromal growth media with weekly 
replacement of 50% of the culture media. For cultures in 
25 cm2 tissue culture flasks, cultures were initiated with 
102 cells of each cell subset. To perform timeline studies, 
at different times, cells are trypsinized and the BCCs are 
positively selected by subjecting the cells twice to 
positive selection with Dynabead conjugated 
anticytokeratin, as described (7). Both stromal and BCC 
cell populations are counted and the purity of each were 
verified by flow cytometry for epithelial and fibroblasts 
antibodies. For epithelial, cells were labeled with PE-
cytokeratin mAb. Indirect labeling was done for stroma, 
first with prolyl 4-hydroxylase mAb followed with PE-
rat anti-mouse IgG. Cells separated by this isolation 
procedure show purity of more than ninety nine percent. 
 
Selecting BCCs from primary cultures  
 
Epithelial cells retrieved from surgical breast tissues, 103-
106, were added to 25 cm2 tissue culture flasks with 7 ml 
of stromal media and stromal cells at 20-40% confluence. 
At confluence, the breast cells are isolated as described 
for co-cultures with cell lines. Cells retrieved are counted 
and the process repeated three times. Cells are then 
studied for cloning efficiency in methylcellulose matrix 
(see below). If the efficiency is <90%, the selection process 
was repeated until cloning efficiencies were >90%. 
 
Clonogenic assays 
 
Clonogenic assays were performed as described (6). 
Briefly, 103  cells/ml were resuspended in 1.2% 
methylcellulose containing media taken from the co-
cultures. One ml of cell suspension was added to 35 mm 
suspension dishes (Nunc, Cat#171099) and the cultures 
were incubated for 1 wk at 37°C. Colonies with >15 cells 
were counted and the cloning efficiency presented as 
percent of total cells placed in culture.     
 
 
Corcoran et al. - An in vitro method to select malignant cells from surgical biopsies of breast cancer patients 
www.biologicalprocedures.com 
11
RESULTS AND DISCUSSION 
 
This study depleted cells from breast biopsies of 
fibroblasts rather than subjecting the cells positively with 
anti-epithelial cells. Although this appears to place the 
breast cells under unnecessary stress we have found loss 
of malignant cells when epithelial cells are selected. 
Thus, if large breast tissues are obtained from the 
surgeon, positive selection could be performed. 
However, if there are variation in surface epithelial, 
crucial subsets might be missed in positive selection. 
 
Cells from breast tissues were placed in suspension and 
then depleted of fibroblasts. The breast cells were either 
cultured alone in stromal media or added to stromal 
cultures. Cultures in stromal media alone did not 
survive. However, those cultured in the presence of BM 
stroma continued to survive until confluent. Initial 
plating of co-cultures comprised BM stroma and BCCs 
(T47D and MDA-MB-330) or non-tumorigenic cells (MCF 
10A or MCF 12A). Figure 1A shows T47D as 
representative of co-cultures with BCCs. Since non-
tumorigenic cells did not survive in co-cultures, these 
experiments are not shown. Controls cultures 
Subsequent passage is represented in Figure 1B. By the 
fourth passage, the cells are able to be cultured in the 
absence of BM stroma (Fig. 1C). Parallel cultures with a 
cell line, T47D are represented in Figure 1D-1F. Cells in 
both 1C and 1F were similar by morphology and by 
phenotype, positive for cytokeratin (not shown). 
 
 
Fig. 1: BC cells from patients were plated on BM stroma in co-culture. 
Cells were passaged together four times. At passage 5, BCC were isolated 
and characterized. Parallel studies were performed using established BC 
lines for comparison. A) Initial co-culture of patient BCC and BM stroma. 
B) Patient BCC and BM stroma at P4. C) Primary BCC isolated from 
stroma after co-culture. D) Initial co-culture of T47D and BM stroma. E) 
T47D and BM stroma at P4. F) T47D isolated from stroma after co-culture. 
Primary cells represent studies from seven patients. Cell line studies 
represent studies with two different cells, each performed seven times. 
 
The results shown in Figure 1 do not prove that the cells 
could be cultured in an anchorage-independent manner. 
To this end, cells represented in Figure 1C were assayed 
in methylcellulose matrix for clonogenic potential. To 
prove that anchorage-independent clones can be derived 
from different stages of BC, the assays were performed 
with cells selected from early to late stages of BC. Table 1 
describes the steps beginning from the number of cells 
selected from Stages M0, I and III BC patients. The 
results showed a cloning efficiency of 82% for the 
malignant cells from the Stage M0 patients, 74% stage 
MI, and 87% Stage MIII. This indicates that anchorage 
independent clones can be selected and expanded from 
various stages of BC. 
 
The co-culture method presented in this report was 
originally designed to select malignant cells from 
surgical breast tissues. The method has been expanded to 
select and expand malignant cells from breast biopsies. 
The method has been shown to be sensitive to select 
malignant cells from small tissue samples, including 
patients with Stage M0 BC. The method is also sensitive 
to select malignant cells from needle biopsies. 
 
In summary, co-culture of cells from breast tissues with 
the stroma still resulted in the selection of the anchorage 
independent malignant cells when the tissues are 
derived from different stages of BC (Table 1). Co-cultures 
from tissues taken from Stage M0 BC patients exhibited 
significantly slower growth rate compared to co-cultures 
with cells from Stage III BC. Figure 2 shows the growth 
of BCCs populations for BCCs taken from patients with 
Stages M0 and III. 
 
 
Fig. 2: Co-cultures of BM stroma and primary BCCs from Stages III and 
M0. At different times during co-cultures, epithelial cells were positively 
selected and then counted. The results are shown as mean ± SD of seven 
different experiments.     
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This is probably due to two reasons: 1. The co-cultures 
are initiated with significantly lower number of 
malignant cells, 2. The early stage of BC might have 
slower growing malignant cells. The co-culture described 
in this report will begin to characterize BCCs from 
different stages of BC. Another application for the co-
culture with BM stromal cells is an excellent tool for 
selecting malignant cells and expanding them in culture 
from small samples for clinical and/or research analyses. 
An important aspect of our model of selecting BCCs in 
stromal co-culture is whether the method is selecting 
specific malignant cells with preference for BM. The 
information is important in light of recent studies shown 
organ-specific potential of distinct BCCs (9). The method 
described in this report could be valuable for future 
research to study differences in BCCs in various sites of 
metastasis. Of note is that passage of the cells in the 
method is meant to eliminate non-tumorigenic cells since 
passage 1 cells are anchorage-dependent. 
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PROTOCOLS 
 
Perform all procedures under sterile conditions. 
 
A. Stromal isolation, 2-step procedure: 
 
Step 1 
 
1.  Get approval for use of human tissues by the Institutional Review Board. 
2.  Obtain bone marrow (BM) aspirates from healthy donors. The aspirate is obtained in a syringe containing 
preservative-free heparin at 50 U/ml. The heparin is diluted in any tissue culture media containing 50 U/ml 
Penicillin and 0.05 mg/ml Streptomycin.  
3.  Count the nucleated cells in the aspirates. 
4.  Add ~ 107 nucleated BM aspirate cells into a 25 cm2 tissue culture flasks (Falcon 3109). Adjust total volume to 7 ml 
of stroma-I media. 
Stroma-I Media: 
•  α-MEM containing 12.5% Fetal Bovine Serum, 12.5% Horse Sera, 0.1% µM Hydrocortisone, 0.1µM 2-
mercaptoethanol, and 1.6mM glutamine; 
•  Incubate flasks in a 37°C incubator with 5% CO2. 
5.  At day 3, remove the non-adherent cells from the flasks and place in a conical tissue culture tube. Combine the 
cells of each donor. Wash residual red blood cells (RBCs) in the flasks with sera-free media and transfer to the 
tubes containing the non-adherent cells. The wash media should be at room temperature. 
6.  Avoid the tissue culture flasks to dry by quickly adding 6 ml of stromal media. Return flasks to the culture 
incubator. 
7.  Centrifuge tubes containing the non-adherent cells at 500 g. If the total volume is ~50 ml, centrifuge for 20-30 min. 
If 10-20 ml, centrifuge for 10-15 min. 
8.  Aspirate media. 
9.  Resuspend pellet in sera-free α-MEM. Determine the total volume to resuspend the cells using the following guide: 
•  Pellets from five flasks should be resuspended in 20 ml α-MEM. If the pellet is from more than five flasks, split 
the cell suspension in multiple 50 ml conical tissue culture tubes.  
10.  Add equal volumes of Ficoll Hypaque to the bottom of each tube. Centrifuge tubes at room temperature for 25-30 
min at 500 g.  
11.  Carefully remove tubes from centrifuge. Aspirate the top layer comprising the suspension media. The next layer of 
white represents the mononuclear fraction (BMNC). Using a Pasteur pipet aspirate the BMNC and transfer into a 
clean sterile conical tissue culture tube. This would require taking a small volume of Ficoll Hypaque. Resuspend 
the cells with 10-20 volumes of sera-free α-MEM.  
12.  Centrifuge tubes at 500 g for 20-30 min at room temperature. 
13.  Aspirate the media. Resuspend the pellet in stroma-I media. The volume of media will depend on the total 
numbers of flasks from which the non-adherent cells were obtained. For example, if the starting numbers were 3 
flasks, add 3 ml of stromal media.  
14.  Remove the tissue culture flasks from the incubator. 
15.  Add 1 ml of cell suspension/flask. 
16.  Re-incubate flasks. Each week replace 50% of the culture media with fresh stromal media until confluence. 
 
Step 2 
 
1.  Trypsinize confluent stromal cells from step 1 by adding 1-2 ml of 0.05% Trypsin with 0.053 Na-EDTA to each 
flask. Incubate in a 37°C-incubator for 5 min. Examine flasks with an inverted microscope. If the cells de-adhered,     
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collect the cells and place into a conical tissue culture tube containing α-MEM with 10% FCS. Pool cells from a 
particular donor. If the cells do not appear de-adhered, tap the flasks and re-examine the flasks. If the cells remain 
adherent, reincubated the flasks until the cells de-adhered. 
2.  Pellet cells by centrifuging at 500 g for 10-15 min. Collect trypsin-sensitive cells and place in a test tube containing 
any type of tissue culture media containing 10% FCS.  
3.  Resuspend cells in Stroma-II media. Add 3 ml of media for cells obtained from each flask. 
Stroma II Media: 
•  α-MEM with 20% heat inactivated FCS.  
4.  Add 1 ml of cell suspension to 25 cm2 tissue culture flask. Adjust the volume to 7 ml with fresh Stroma-II media.  
5.  At cell confluence, repeat cells passages, #1-4 of Step 2. 
6.  Repeat step 5 four times. 
7.  Confirm the purity of stromal cells by immunofluorescence using the following antibodies: 
•  Anti-CD14 (PE, FITC or any other fluorochrome), expected to be negative. 
•  Anti-fibroblasts (non-overlapping fluorochrome, i.e., different from the conjugate used for anti-CD14. For 
example, if anti-CD14 is conjugated to PE, anti-fibroblasts should be conjugated to any fluorochrome but PE, 
expected to be positive). 
 
Immunofluorescence stain 
 
1.  Collect cells in a polypropylene test tube 
2.  Spin cells 10 minutes at 150rpm 
3.  Resuspend cell pellet in 1XPBS to wash 
4.  Spin 10 minutes at 150rpm 
5.  Aspirate PBS and repeat 
6.  Resuspend cell pellet in 1-2ml PBS 
7.  Add 1° Antibodies (CD14 and Anti-fibroblast) 1:1000 
8.  Incubate 1-2 hours, shake every 10minutes 
9.  Wash 2 times with 1XPBS 
10.  Add 300µl of PBS 
11.  Read on the Flow Cytometer 
 
* If CD14 is positive, continue to passage cells since macrophages are insensitive to trypsinization. 
 
B. Isolation of epithelial cells from surgical breast tissues 
 
1.  Obtain surgical breast tissue sample from excess patient sample. (Obtain informed consent from patients based on 
a protocol approved by the Institutional Review Board) 
2.  Flush cells from the tissue as follows: 
•  Forcefully passing any sera-free tissue culture media through a 1-cc syringe. 
•  Use a sterile serrated tip tweezers to separate the cells within the tissue samples. 
3.  To avoid cell clumps, place petri dishes containing cell suspension at ~30-45 degree angle. This would allow for 
large clumps to remain at the top. Collect the clump-free cell suspension in sterile conical tissue culture tubes. Fill 
the tube with any sera-free media. Pellet cells by centrifuging at 500 g for 10-15 min at room temperature.  
4.  Resuspend the cells in Ca++/Mg++-free PBS (pH7.2). 
5.  Deplete the cell suspension of fibroblasts with anti-fibroblast microbeads from Miltenyi Biotec (Cat#130-050-601) 
using manufacturer’s instructions. The following is a brief outline of the protocol used to deplete fibroblasts 
followed by positive selection of epithelial cells: 
•  Resuspend cells at 107/ml in PBS.     
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•  Add anti-fibroblast microbeads. This step deviates from manufacturer’s suggestion. Incubate at room 
temperature for 1-2 h. Mix at 10-min intervals. Note: The incubation time could vary based on the degree of 
malignancies in the biopsies. Consistently, 1-2 h incubation period has shown consistent results.  
•  Select the magnetic-coupled fibroblasts. Proceed with the negative fraction. Use an aliquot of cells and 
determine by immunofluorescence if the negative fraction is devoid of fibroblasts. To do this, label cells with 
FITC-anti-fibroblast at 1/1000 dilution final concentration. Determine non-specific labeling with FITC-isotype 
control. Immediately examine cells microscopically or by FACscan. If the results show the presence of 
fibroblasts, repeat the selection process until labeling for fibroblasts determined depletion. 
6.  Positively select epithelial cells using human epithelial antigen (HEA) microbeads from Miltenyi Biotec., according 
to manufacturer’s instructions. 
•  Resuspend cells at 107/ml in 1X PBS 
•  Add anti-epithelial microbeads. Incubate at room temperature for 2 h. Mix at 10-min intervals.  
•  Select the magnetic-coupled epithelial cells. Remove the negative fraction. Resuspend the positive fraction in 
media. Use an aliquot of cells and determine by immunofluorescence if the positive fraction is pure. To do this, 
label cells with FITC-anti-CD31 at 1/1000 dilution final concentration. Determine non-specific labeling with FITC-
isotype control. Immediately examine cells microscopically or by FACscan. If the results show the presence of 
endothelial cells, repeat the selection process until labeling for epithelial cells determined depletion. 
•  Plate epithelial cells in appropriate BCC media 
 
C. Co-culture of BCC and BM 
 
1.  Add equal numbers of BM stromal cells and primary breast cells into flasks containing stromal media II. 
2.  Replace 50% of the media weekly until confluence. 
3.  Use the method above for positive selection of epithelial cells. 
4.  Reestablish co-cultures with fresh stroma and the selected epithelial cells. 
5.  Repeat steps 3 and 4 for up to four times. 
6.  Test the malignancies of the epithelial fraction in clonogenic assays. 
 
D. Clonogenic assay 
 
1.  Add Breast cancer cells 103/ml in 1.2% methylcellulose matrix with stromal media 
2.  Add 1ml of cell suspension in 35 mm Nunc suspension dishes. 
3.  Incubate one week at 37°C 
4.  Count colonies with >25 cells 
 
Preparation of methylcellulose 
 
Note: do not use fresh methylcellulose. Freeze at least 2 month prior to use, this helps the methylcellulose to dissolve. 
 
Materials 
 
•  Methylcellulose, 4000 centipose – Fisher Scientific (Cat# M-352) 
•  2 liter Erlenmeyer flask 
•  Large magnetic stir bar (must be large enough to stir methylcellulose at semisolid phase) 
•  1.5 liters of endotoxin-free double distilled water 
•  Autoclavable measuring cylinder 1L 
•  Sodium bicarbonate solution (7.5%)  
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Autoclave 
 
•  12g (1.2%) methylcellulose (weigh in beaker then cover with double layer of aluminum foil) 
•  Erlenmeyer flask with stir bar 
•  Measuring cylinder, covered with double layer of foil 
•  1.5 liters of Endotoxin free double distilled water (3-500ml bottles) 
(Autoclave dry and wet items separately) 
 
Methylcellulose (1.2%) 
 
•  Chill 1 500ml bottle of water to 4°C 
•  Prepare 2x Iscove’s Media (if Iscove’s is not available, use 2x α-MEM)  
•  Set up a stirring/hot plate under sterile hood. Slowly pour methyl cellulose in 300ml boiling distilled water.  
•  Stir vigorously while pouring. 
•  Stir just under boiling until the mixture is homogenous. 
•  Add 200ml cold distilled water 
•  Cool to room temperature. Add 500 ml 2x Iscove’s (room temp) while stirring 
•  Add 26.7 ml sodium bicarbonate (7.5%) 
•  Continue stirring in the cold room for 48 hours 
•  Aliquot in 50ml tubes, store at -20°C 
•  Thaw at 4°C prior to use 